A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression

NCT04599855 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

477

Enrollment

INDUSTRY

Sponsor class

Conditions

Depressive Disorder, Treatment-Resistant

Interventions

DRUG: Esketamine 56 mg
DRUG: Esketamine 84 mg
DRUG: Placebo

Sponsor

Janssen Research & Development, LLC